** Life sciences firm Avantor's shares AVTR.K fall 4.37% to $20.75 premarket
** Co posts Q4 sales of $1.69 billion, which missed analysts' estimates of $1.71 billion, as per data compiled by LSEG
** Sales hurt by foreign currency and the divestiture of its clinical service business
** Co divested its clinical service business to Audax private equity firm in a deal valued at ~$650 million last year
** Sees 2025 adj profit in the range of $1.02 to $1.10 per share
** Analysts estimate annual profit of $1.10 per share
** Up to last close, stock had fallen 11.93% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。